Femasys (NASDAQ:FEMY) Stock Gets Downgrade from Wall Street Zen

Femasys (NASDAQ:FEMY) was downgraded by research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other research analysts also recently issued research reports about the company. Weiss Ratings downgraded Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Maxim Group cut their price objective on Femasys to $10.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Finally, Lake Street Capital dropped their price objective on Femasys to $10.00 and set a “buy” rating on the stock in a report on Tuesday, August 18th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Femasys has a consensus rating of “Moderate Buy” and an average price target of $50.00.

Femasys Price Performance

FEMY stock opened at $1.37 on Friday. The firm has a 50-day moving average of $2.29 and a two-hundred day moving average of $6.18. Femasys has a one year low of $1.30 and a one year high of $22.20. The company has a current ratio of 2.14, a quick ratio of 0.55 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $11.48 million, a PE ratio of -0.39 and a beta of -2.13.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings results on Friday, August 14th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.02). The firm had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.73 million. Femasys had a negative net margin of 534.36% and a negative return on equity of 225.97%.

Insider Activity at Femasys

In other Femasys news, CFO Dov Elefant purchased 15,625 shares of Femasys stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $3.20 per share, for a total transaction of $50,000.00. Following the acquisition, the chief financial officer owned 15,625 shares in the company, valued at $50,000. This trade represents a ? increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kathy Lee-Sepsick purchased 15,625 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average price of $3.20 per share, for a total transaction of $50,000.00. Following the transaction, the chief executive officer owned 15,625 shares of the company’s stock, valued at $50,000. This trade represents a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 38,750 shares of company stock valued at $124,000. Company insiders own 7.75% of the company’s stock.

Femasys Company Profile

Femasys Inc is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures.

Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.